Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework.

Last updated on 22-8-2019 by Anonymous (not verified)

Peer reviewed scientific article



As the demand for human papillomavirus (HPV)-related cervical screening increases, emerging HPV tests must be evaluated robustly using well-annotated samples, such as those generated in the Validation of HPV Genotyping Tests (VALGENT) framework. Through VALGENT, we assessed the performance of the BD Onclarity HPV assay, which detects 14 high-risk (HR) types and resolves six individual types and three groups of types. Consecutive samples from a screening population (n = 1,000), enriched with cytologically abnormal samples (n = 300), that had been tested previously with the GP5+/6+ PCR enzyme…

Associated health topics:

QR code

QR code for this page URL